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Abstract
Pilot Study of Behavioral Activation as Adjunct Treatment for Depression in Primary Care
Lindsay E. Toler
Many individuals receiving care at a predominantly free primary health care clinic in the
northern part of West Virginia are experiencing depression, and medication therapy is the most
common form of management with limited resources for psychosocial treatment. Brief
psychosocial therapy interventions provided by the primary care provider should be explored as
an adjunct treatment for this population in the primary care setting.
A pilot study was conducted to explore the integration of behavioral activation, a brief
psychosocial intervention focused on decreasing depressed behavior by increasing nondepressed
behavior to reinforce corresponding improvements in mood. Eligible patients were invited to
attend five sessions once for five weeks. Visits were conducted according to the revised manual
for Behavioral Activation Treatment for Depression. Data collection included measurements for
adherence to treatment, PHQ-9, and BADS scores.
Three primary aims were evaluated for this project: 1) To assess the feasibility of
implementing this intervention in this clinic population; 2) To decrease overall PHQ-9 scores and
increase overall BADS scores; and 3) To increase medication adherence in conjunction with a
psychosocial intervention.
The feasibility evaluation of this project was performed according to Bowen’s feasibility
criteria and showed mixed results. Data suggests there was no statistically significant difference
in depressive symptoms or daily functioning but minor improvements were noted, indicating
potential clinical significance. Limitations of this study included low patient enrollment and the
COVID-19 pandemic. Future research could include implementation of this intervention in an
integrated care center, larger clinic, or with a different clinic population.
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Introduction
Depression is a prevalent illness in West Virginia (WV DHHR, 2018). Many individuals
receiving care at a predominantly free primary health care clinic in the northern part of the state
are experiencing depression, and medication therapy is the most common form of management
as there are limited resources for treatment like psychiatry or formal counseling. Despite
medication management, a noticeable amount of depression screenings for ongoing monitoring
show moderate to severe depression scores without improvement. Psychosocial therapy
delivered by primary care providers should be explored as an adjunct treatment for this
population in primary care settings. Current practice must be modified to improve depressive
illnesses and their sequela in this population as patients with untreated depression suffer from
greater comorbidities and earlier mortality than their non-depressed counterparts (Coryell, 2018).
Background
A diagnosis of major depressive disorder (MDD) requires the presence of five or more
symptoms over a two-week period that include either depressed mood or anhedonia (American
Psychiatric Association [APA], 2013). People with major depression may experience a lack of
interest or pleasure in daily activities, significant weight loss or gain, insomnia or excessive
sleeping, lack of energy, inability to concentrate, feelings of worthlessness or excessive guilt,
and recurrent thoughts of death or suicide (American Psychological Association, 2020).
According to the Center for Disease Control (CDC, 2015) between the years 2013 and 2016,
8.1% of Americans aged 20 and older were diagnosed with depression.
Significance of Project
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The lifetime prevalence of major depression in the United States is 17% (Krishnan, 2019).
The prevalence of depression in West Virginia is significantly higher at 23.8% (WV DHHR,
2018). Depression is associated with coronary heart disease (CHD), diabetes mellitus (DM),
Parkinson’s disease (PD), stroke CVA), and dementia (Coryell, 2018). These associations could
be due to the disease process itself or impaired functioning related to the disease (Krishnan,
2019). Depression is also associated with earlier mortality. People with serious mental illnesses
die about 25 years earlier than the general population (Mauer, 2006). Studies show that the
likelihood of mortality due to any cause is about 50 to 100 % greater in depressed individuals,
compared with nondepressed individuals (Coryell, 2018). Death due to suicide, homicide, and
accidental death is also increased in patients with depression (Coryell, 2018). The most recent
data from the CDC for West Virginia shows a steady increase in deaths associated with suicide,
homicide, firearms, and overdoses during the years 2014 to 2017 (CDC, 2018). These statistics
indicate a significant need for increased access to treatment for depression in West Virginia.
Center for Disease Control statistics demonstrate a correlation between depression and
socioeconomic status. This data shows that 15.8% of adults from families living below the
federal poverty level have depression, but the prevalence of depression decreases as family
income levels increase (Brody, Pratt, & Hughes, 2018). In West Virginia, depression is
significantly higher among people with less than a high school education and an annual
household income of less than $15,000 (WV DHHR, 2018). In a sample of patients with a lower
socioeconomic status at a free, rural, primary care clinic in West Virginia, 39% of patients had a
diagnosis of depression (McCrone et al., 2007). Factors predictive of depression were younger
age, lower education level, alcohol use, and unemployment (McCrone et al., 2007). Services for
medication and psychiatry referral exist in the clinic of interest (L. Jones, personal
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communication, December 15, 2019); however, low availability of resources such as funding and
transportation make the likelihood of success for outpatient psychiatry referrals unreliable.
Moreover, West Virginia is not prepared to meet the need for specialty treatment of mental
illness. The state ranks 49th in mental health workforce availability with one provider for every
890 patients (Hellebuyck, Halpern, Nguyen, & Fritze, 2019). According to the CDC, 10.4% of
all primary care visits were used to address depressive symptoms (2015). They also note that
between the years 2011 and 2014, 12.7% of people aged 12 and older used antidepressant
medication (Pratt, Brody, & Gu, 2017). Amidst the current treatment options in primary care, the
rate and severity of depression appear to be increasing (WV DHHR, 2018).
Due to this shortage of mental health providers, psychosocial treatments for depression
should be considered for integration into primary care services. Treatments must be timely and
providers must be easily trained to enhance feasibility and engagement. While cognitivebehavioral therapy is the gold standard for depression, it requires a significant time commitment
and must be implemented by providers with specialty training. Behavioral therapy is not a novel
treatment, but interest in its usefulness and simplicity has been recently renewed. The behavioral
approach was pioneered by Ferster (1973) and Lewinsohn (1974), both of whom recognized a
link between avoidant behavior and depression. They recommended the use of behavioral
activation strategies to increase positive reinforcement with the environment and subsequently
improve mood (Ferster, 1973 & Lewinsohn, 1974). There are two current evidence-based
methods for behavioral activation strategies: Behavioral Activation and the Brief Behavioral
Activation Treatment for Depression (Turner & Leach, 2012). Behavioral activation strategies
emphasize the importance of reinforcement as a means of treatment (Turner & Leach, 2012).
Recent approaches to behavioral activation focus on decreasing depressed behavior by increasing
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nondepressed behavior to reinforce the corresponding improvements in mood that these actions
produce (Turner & Leach, 2012). During treatment with behavioral activation, the provider
works with the patient to identify patterns of reinforcing behavior and the contingencies between
those behaviors and their consequences (Turner & Leach, 2012). With activation techniques, an
automatic consequence of increasing positively reinforcing behaviors results in the decrease of
negatively reinforcing behaviors that perpetuate depressive symptoms (Turner & Leach, 2012).
Behavioral activation itself involves collaboration between provider and patient to identify
behaviors that elicit and reinforce depressive symptoms, and then choosing positive behaviors
for activation (Turner & Leach, 2012). Due to its simple, straightforward technique and
implementation without complex training, behavioral activation has the potential to be a valuable
treatment for depression in primary care.
Problem Statement
Patients with a lower socioeconomic status tend to have an increased rate of depression
(Brody, Pratt, & Hughes, 2018; WV DHHR, 2018). At a rural, predominantly free, primary care
clinic in northern West Virginia, a large percentage of patients with these characteristics are
diagnosed with depression (McCrone et al., 2007). Screening during treatment often reflects little
to no improvement in depression scores (C. Wang, personal communication, December 15,
2019). Due to a lack of resources, referral to higher levels of specialty care is often impractical.
Changes in clinician practice are being explored to address persistent depressive symptoms.
Purpose of Project
This pilot study implemented the Brief Behavioral Activation Treatment for Depression in
consenting patients with depression. This intervention has been shown to decrease severity of
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symptoms and improve patient behaviors associated with depression. Implementing behavioral
activation as part of depression treatment in a low socioeconomic status population at a primary
care clinic had the potential to improve depression outcomes.
Literature Review
An advanced literature search was conducted on December 14, 2019 using EbscoHost.
Most notable databases included were Cochrane Library, CINAHL, Medline PubMed, and
PsycINFO. Searches included various combinations of key words “behavioral activation,”
“Behavioral Activation for Treatment of Depression,” “primary care,” “primary care clinic,” and
“depression.” Inclusion criteria were human subjects, English language, and publication between
2000 and 2019. Exclusion criteria included studies on forms of depression other than major
depressive disorder, depression associated with other illnesses, and studies with an adolescent
and/or child population. After duplicates were removed and inclusion and exclusion criteria were
applied, nine articles were found suitable for review (see Appendix A for evidence table with
more complete study details).
The first article chosen for review was a randomized control trial by Dimidjian et al.
(2006) comparing behavioral activation, cognitive therapy, anti-depressant medication (ADM),
and placebo control (PLA). The purpose of this study was to assess the effectiveness of
behavioral activation (BA) as a treatment for major depression compared to cognitive therapy
(CT) and ADM in the presence of a placebo control. Participants were randomly assigned to a
treatment group using a computer-generated randomization list. Treatment groups consisted of
BA, CT, ADM, or PLA. Severity of depression was used as a stratification of randomization.
There was significant overall improvement across all conditions in the high-severity subgroup on
the BDI (p < 0.0001) and the HRSD (p < 0.0001). Participants in the BA condition improved
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significantly more per week than participants in the CT condition on the BDI (p = 0.029) and the
HRSD (p = 0.03). Patients in the ADM condition also improved significantly more per week
than participants in the CT condition on the BDI (p = 0.007) and the HRSD (p = 0.022). No
significant differences were found comparing participants in the BA and ADM conditions on
BDI or HRSD. There were significant overall improvements across all conditions in the lowseverity subgroup on the BDI (p < 0.0001) and the HRSD (p < 0.0001), but there was no
evidence of differences in improvement between treatments on the BDI or HRSD. For rates of
response in the high-severity subgroup, data showed that significantly more participants in the
BA condition met response criteria compared to those receiving CT (p = 0.048) or ADM (p =
0.027). For rates of remission in the high-severity subgroup, data showed significant differences
between treatments on the HRSD (p = 0.012) and a significantly greater percentage of remission
for participants in the BA condition compared with participants in the ADM condition (p =
0.002). From these findings, authors concluded that BA is similarly efficacious to ADM and
more effective than CT. In more severely depressed patients, BA treatment resulted in a
significantly larger number of participants reaching remission, and keeping a higher percentage
of patients in treatment. These results highlight the importance of simple behavioral strategies in
the treatment of depression.
The next article for review is a meta-analysis conducted by Cuijpers, van Straten, and
Warmerdam (2007). The purpose of this meta-analysis was to examine the effects of activity
scheduling (AS) on depression, the effects of activity scheduling compared to other treatments,
and the long-term effects of activity scheduling. The literature included 16 studies with a total of
780 participants for this meta-analysis. Results showed that the mean effect size between
activity scheduling and control condition was large, favoring activity scheduling. The pooled
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effect size between activity scheduling and other psychological treatments was small, favoring
activity scheduling but without a significant difference. The pooled effect size between activity
scheduling and cognitive therapy was small, favoring activity scheduling. The pooled effect size
between activity scheduling and a combination of CT and AS was small, favoring the
combination of CT and AS. The pooled effect size between CT and a combination of CT and AS
was small, favoring the combination of CT and AS. The effect size between activity scheduling
and antidepressant medication was small, favoring activity scheduling. The effects of activity
scheduling compared to a control condition at follow-up was large at two months and moderate
at six months, suggesting some corroboration for the effectiveness of activity scheduling at longterm follow-up. The effect size between activity scheduling and CT at 1-2 months and 4-6
months was small, indicating nonsignificant differences between CT and activity scheduling at
follow-up. From this data, authors concluded that activity scheduling is effective in the treatment
of depression in adults. The overall effect size of activity scheduling is large, and similar to
effect sizes found for other psychological treatments and antidepressants.
The next article for review is a meta-analysis by Ekers, Richards, and Gilbody (2007). The
purpose of this study was to compare the effectiveness of behavioral therapy (BT) interventions
to other psychosocial treatments and control conditions. Twenty studies were included with a
total of 1,109 participants. Interventions in these studies included BT, treatment as usual (TAU)
or control condition, CBT/CT, brief psychotherapy, or supportive counseling. Results for studies
comparing BT and control conditions showed a significant difference between symptom level
scores favoring BT over control (p < 0.001). There were also significantly larger rates of
recovery in BT conditions than control (p = 0.03). Results for studies comparing BT and
CBT/CT showed no difference in depression levels at post-treatment (p = 0.46). Results for
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studies comparing BT and brief psychotherapy showed a significant difference between
symptom level scores favoring BT over psychotherapy (p = 0.01). There were significantly
higher rates of recovery observed in the BT condition than psychotherapy (p = 0.01). Results for
studies comparing BT and supportive therapy showed a significant difference between
conditions favoring BT (p = 0.02). From these results, authors conclude that BT is an effective
treatment for depression and is superior to control conditions, supportive counseling, and brief
psychotherapy. Authors also concluded that BT and CBT resulted in equivalent results with no
statistically significant differences in post-treatment and follow-up symptom levels, recovery
rates, or drop outs. These findings indicate that BT is as effective and acceptable as CBT/CT.
The authors mention that data from this study did not support the assumption that BT may afford
shorter training of less-qualified individuals to relieve the burden on therapist availiabity and
demand; however, a meta-regression examining the impact of level of training for delivery of BT
did not find that superior outcomes were associated with higher level of qualifications. Overall,
authors conclude that BT is an effective treatment for depression with equal, or better, outcomes
than treatments currently recommended.
The next article for review by Dobson et al. (2008) is a randomized control trial that builds
on the findings of the RCT by Dimidjian et al. published in 2006. The purpose of this study is to
determine the sustained effectiveness of prior CT, BA, or continued ADM in the presence of a
placebo control, and whether the effects of CT or BA extended into the second year of follow-up.
This study measured the rates of relapse or recurrence of depression in the participants of the
Dimidjian et al. study. Assessments were conducted biweekly for the first two months of the
first-year follow-up phase, and then at three, six, 12, 13, 14, 18, and 24 months. Data showed
that relapse was highly likely at the beginning of the first follow-up year, especially for those
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withdrawn onto placebo. Rates of relapse during the first follow-up year showed that active
treatments (CT, BA, or ADM) resulted in significantly lower rates of relapse than withdrawal to
placebo (p = 0.04). Taken individually, prior CT was significantly better than withdrawal to
placebo (p = 0.02) and prior BA resulted in lower rates of relapse at a nonsignificant level (p =
0.09). Rates of relapse were not significantly different between continued ADM and withdrawal
to placebo (p = 0.33). Prior exposure to CT reduced the risk for relapse by 64% compared to
medication withdrawal, while continued ADM reduced the risk for relapse by about 33%, and
prior exposure to BA reduced the risk for relapse by 51%. Participants in the continued ADM
condition were withdrawn to placebo at the beginning of the second-year of follow-up. Rates of
recurrence during the second-year of follow-up were lower in the prior CT and BA conditions
than prior continued ADM but not with a significant trend (p = 0.06). Overall, prior CT and BA
were significantly superior to continuation of ADM (p = 0.04) and medication withdrawal. Prior
exposure to CT was significantly superior to continued ADM (p = 0.02) and prior exposure to
BA showed a nonsignificant trend in the same direction (p = 0.08). From these results, authors
concluded that prior exposure to either CT or BA resulted in an ongoing effect that was at least
as effective as continued medication treatment, including the prevention of relapse and possibly
recurrence.
The next article for review is a randomized control trial by Gawrysiak, Nicholas, and
Hopko (2009). The purpose of this study was to assess the effectiveness of a single-session BA
intervention based on the BATD protocol. Participants were recruited online from an
introductory psychology course at a Southeastern university. Eligible participants who agreed to
take part in the study were randomly assigned to the treatment or control group. The intervention
protocol was adapted from the BATD treatment manual by Lejuez, Hopko, and Hopko in 2001.
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The treatment was reduced from a nine-session protocol to one session, which resulted in
decreased activity scheduling and exclusion of behavioral contracting strategies. Outcome
measures were assessed using the BDI, to measure depression symptom severity, the EROS, to
measure environmental reward and response-contingent positive reinforcement (RCPR) with
higher scores suggesting increased environmental reward, the BAI, to measure symptoms of
anxiety, and the MSPSS, to measure the social support from participants’ family and friends,
with higher scores indicating decreased social support. The authors also measured adherence to
treatment using the weekly behavioral checkout sheets that participants returned to clinicians at
the follow-up visit. Analysis showed a significant interaction between Group x Time on both the
BDI (p < 0.01) and EROS (p < 0.001) and large effect sizes on the BDI (1.61) and EROS (1.14)
demonstrated clinically significant improvements. There was a trend toward greater social
support in the treatment group relative to control at post-treatment (p = 0.08) with a moderate
effect size (d = 0.70). Reliable change indices were calculated for each measure and showed that
93% of individuals in the BATD group significantly improved on the BDI compared with 31%
in the control group, that 64% of individuals in the BATD group significantly improved on the
EROS compared to 0% of participants in the control group, and that 29% of individuals in the
BATD group significantly improved on the MSPSS compared with 6% in the control group.
Change-score data showed a strong relationship between increased environmental reward with
decreased depression (p < 0.01), anxiety (p < 0.05), and increased social support (p < 0.01).
Authors concluded that there was evidence that a brief BA intervention was effective in reducing
depressive symptoms, increasing response-contingent positive reinforcement, and increasing
social support. Data shows that a single-session of the BATD intervention resulted in significant
reductions in depressive symptoms and increased environmental reward, suggesting that
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shortened treatments may be effective and efficient in reducing depressive symptoms of
moderately depressed students.
The next article for review is a meta-analysis by Mazzucchelli, Kane, and Rees (2009).
The purpose of this meta-analysis was to identify all randomized control trials (RCT) of
behavioral activation (BA), establish the effect of this method, and compare the effectiveness of
its variants. Interventions included pleasant activities, self-control, contextual behavioral
activation, and Behavioral Activation Treatment for Depression (BATD). Comparators included
nontreatment, cognitive behavioral therapy/cognitive therapy (CBT/CT), and a blanket group of
other treatments such as psychodynamic therapy or supportive counseling. After exclusion, 34
studies with a total of 2,055 participants were chosen. Results showed a large overall effect size
in patients with elevated scores of depressive symptoms favoring BA over control conditions.
This finding is similar to previous meta-analyses. Results also show a large, significant overall
effect size favoring BA in patients meeting criteria for depressive disorder. However,
comparisons between BA and CBT/CT showed no difference at post-test or follow-up, indicating
that these treatments were equally effective in the short- and long-term. From the evidence,
authors concluded that BA interventions are effective for the treatment of depression in adults,
and the behavioral activation approach could be designated as a well-established treatment for
depression.
The next article for review by Richards, et al. (2016) is a randomized, controlled, openlabel, noninferiority trial. The purpose of this study was to assess clinical efficacy and costeffectiveness of BA intervention compared to CBT in adults with depression. Patients were
randomly assigned to treatment groups using computer-generated randomization and were
stratified by depression severity according to PHQ-9 scores, antidepressant use/nonuse, and
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recruitment site. The BA intervention was delivered to participants by junior Mental Health
Workers (MHWs) and the CBT intervention was delivered by experienced psychologists.
Follow-up assessments were conducted at six, 12, and 18 months. The primary outcome measure
was self-reported depression severity using the PHQ-9 at 12 months. Secondary outcome
measures included PHQ-9 scores at six and 18 months, diagnostic status, number of depression
free days between follow-up points as determined by structured clinical interview, and healthrelated quality of life at six, 12, and 18 months using a 36-Item Short Form Survey. The
modified intention-to-treat (mITT) population is comprised of all participants randomized with
complete data and the per-protocol (PP) population was comprised of participants randomized
with complete data who completed at least eight treatment sessions. Authors found no evidence
of inferiority between these two populations. Authors also found no evidence of a significant
between-group treatment interaction across the mITT or PP group for the primary outcome at 12
months as stratified by depression severity, antidepressant use, and recruitment site. Data showed
that BA was not significantly different from CBT with relation to anxiety, depression status,
depression-free days, or anxiety diagnoses for either the mITT or PP populations at 12 months.
Data also showed that 61% to 70% of mITT and PP participants in both treatment groups met the
criteria for recovery from depression with response to treatment at 12 months. Authors found no
evidence of a difference between the BA and CBT groups with a nonsignificant time by
treatment effect interaction for both mITT and PP populations. Authors did find a significant
difference in average cost for intervention between the two groups in favor of BA (p < 0.0001),
but no differences between categories of cost (hospital care, community health care, or
medication) or in total cost. The mean health-related quality of life score was slightly higher for
participants in the BA group at all follow-up points with resulting quality-adjusted life years
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(QALY) also higher for participants in BA. Authors concluded that BA treatment for depression
is non-inferior to CBT in terms of reduction in depressive symptoms and is more cost-effective
than CBT treatment. Overall, authors believe that the results of this study challenge the
dominance of CBT due to findings that suggest therapies that can reduce the need for costly
professional training, reduce patient waiting times, and increase access to psychological
therapies.
The next article for review is a benchmark-controlled trial (BCT) by Luoto et al. (2018).
The purpose of this study is to examine the effects of BA in a group of depressed patients in their
natural treatment setting and compare them to treatment as usual with regard to functional
recovery, service use, dropout rate, and mortality. After matching, authors found that statistically
significant differences between groups were baseline Global Assessment of Functioning (GAF)
scores and frequency of personality disorders as a secondary diagnosis. BA treatments were
implemented by trained personnel, including registered psychiatric nurses, psychiatric practical
nurses, and psychologists. Follow-up appointments were scheduled with a clinical research nurse
at six, 12, and 24 months after intervention. Patients in the control group received TAU
according to the protocols of their specific interventions and follow-up data was gathered from
patient case-notes at six, 12, and 24 months after treatment by estimating GAF scores and
obtaining information about alcohol use. For treatment and control conditions, data concerning
frequency of outpatient visits, number of hospital days, and dropout rates were obtained from
patient records at six, 12, and 24 months following treatment. Results showed that mean scores
for participants in the treatment group on MADRS at baseline was 23.2 points, 13.1 points at 6
months, 9.93 points at 12 months, and 8.31 points at 24 months. The improvement of MADRS
scores for treatment group participants was statistically significant in every follow-up period.
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Again, for treatment group participants there was no difference in GAF scores between baseline
and follow-up at six months. However, at 12- and 24-months follow-up the estimated
improvement in GAF scores was significantly better in the intervention group (p = 0.036). Data
showed no between-group differences in number of outpatient visits during any follow-up
period. The need for hospitalization was similar between treatment and control groups during all
follow-up periods. There were no differences between treatment and control groups with regards
to dropout rates in any follow-up period (p = 0.79, p = 0.86, p = 0.51, respectively). During all
follow-up periods, there was no significant difference in mortality between groups (p = 0.23).
Authors consider this study to be highly representative of the standard patient population in
natural practice settings. Due to this capability for generalization, they believe conclusions are
useful in real world practices. Data from this study shows that depressive symptoms of
participants in the treatment group seemed to improve at follow-up periods, and the authors
believe that BA may be a useful tool for treatment. Authors also noted that participants in the
treatment group showed a greater improvement in functional ability than those in the control
group and believe this is essential to patients’ daily life. Rates of hospitalization and dropout
were not significantly different between treatment and control groups. Overall, authors found an
improvement in depressive symptoms and a trend toward functional recovery in patients treated
with BA compared to TAU.
The last article for review by Funderburk, Pigeon, Shepardson, and Maisto (2019) was a
non-randomized, non-controlled intervention trial. The purpose of this study was to address the
need for a brief depression treatment suitable for primary care. Data showed a significant
reduction in depressive symptoms based on PHQ-9 scores (p = 0.001). Data also revealed patient
engagement of 36%, 1%, and 32% at appointments two, three, and four respectively based on
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completed activity logs. A CSQ rating of 26.7 out of 35 indicated a high level of patient
satisfaction, including satisfaction with the number, duration, and format of appointments.
Authors concluded that results of the study supported the feasibility, acceptability, and efficacy
of BA-PC. Patients reported high levels of satisfaction with the intervention, high likelihood of
continuing activity scheduling after treatment, and perceived improvements in depressive
symptoms which was supported by a decrease in PHQ-9 scores. Authors do admit that BA-PC
may not entirely resolve depressive symptoms, and that a majority of patients did not report a
clinically significant reduction in symptoms as defined by their criteria; however, a 68%
treatment response showed a majority of patients reported symptom reduction. Summarily, this
study showed BA-PC was well received by patients, could be delivered with high fidelity, and
may result in an improvement of depressive symptoms.
Literature Synthesis
This review produced studies that were mostly located in the upper tiers of evidence-based
literature with a majority being randomized control trials or meta-analyses. All articles were
published in peer-reviewed journals lending credibility to study findings. They were also
replicable and generalizable. While not all studies found behavioral activation to be superior to
cognitive-behavioral therapy or cognitive therapy, all studies found BA to be equivalent to
CBT/CT. All studies also found BA to be superior to placebo, control, antidepressant
medication, and other forms of psychosocial intervention.
Theoretical Framework
This project was based on the Theory of Symptom Management. The Theory of Symptom
Management was first introduced in 1994 by faculty at UCSF School of Nursing and revised in
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2001. According to the theory, signs and symptoms of illness disrupt functioning and bring
patients into the health care system, usually after self-care management strategies fail. This
theory proposes a relationship between three concepts, provides a structure to understand the
relationship between concepts, and provides a framework for considering interventions and
outcomes (Smith & Liehr, 2008).
The Theory of Symptom Management is composed of three concepts. These concepts
include symptom experience, symptom management strategies, and symptom status outcomes.
Symptom experience is the “simultaneous perception, evaluation, and response to a change in
usual feeling” (Smith & Liehr, 2008, p. 147). If a symptom occurs with enough frequency and
severity to be perceived as distressing and interfering with life, the patient will seek help for
more effective ways to minimize or stop the symptom. Symptom management strategies are
“efforts to avert, delay, or minimize symptom experience” (Smith & Liehr, 2008, p. 147).
Management strategies are effective by reducing frequency of symptom experience, minimizing
severity of symptom experience, and relieving the distress associated with symptom experience.
Symptom status outcomes are specific, measurable outcomes that are evaluated after the
implementation of a strategy. Outcomes are obvious changes in symptom status where the
symptom is less frequent, intense, or distressing (Smith & Liehr, 2008).
This theory is a framework for the study and development of symptom management
strategies and apply to this project. Theoretically, patients with low socioeconomic status will
experience depressed mood, anhedonia, and other symptoms of depression (Brody, Pratt, &
Hughes, 2018). These symptoms cause the patient to suffer some type of distress. They then try
to manage or eliminate this distress on their own but frequently visit their primary care provider
when self-management is inadequate. Primary care providers then enact interventions that have
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been shown to alleviate or eliminate symptom experience. In this situation, it seems that typical
management strategies are not adequate to improve symptom experience. Successful
interventions by the primary care provider should improve the distress of depression symptoms.
Using this framework, new interventions can be implemented and evaluated for symptom
management strategy.
Project
Intervention Plan
Treatment guidelines from the National Institute for Health and Care Excellence recognize
that BA is an effective treatment for depression and should be considered as an intervention for
patients with depressive symptomology ([NICE], 2009). This pilot study evaluated the
effectiveness of the revised Behavioral Activation Treatment for Depression (Lejuez, Hopko,
Acierno, Daughters, & Pagoto, 2011) combined with treatment as usual implemented in a
predominantly free primary care clinic in northern West Virginia serving a population of
individuals with a low socioeconomic status.
The intervention used in this pilot study was a shortened version of the revised Behavioral
Activation Treatment for Depression (BATD-R) by Lejuez, Hopko, Acierno, Daughters, and
Pagoto (2011). Direction was taken from the revised treatment manual. Specific revisions to the
revised treatment include greater emphasis on treatment rationale, more clarity on life areas,
values, and activities, simplified and fewer treatment forms, enhanced procedural details, and a
revised daily monitoring form for low literacy (Lejuez, Hopko, Acierno, Daughters, & Pagoto,
2011). The original procedure in its extended format consists of 10 sessions. These meetings
include five active treatment sessions and five sessions for review and post-treatment planning.
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(Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011). Studies have shown the effectiveness of
BA in as little as one to two sessions (Gawrysiak, Nicholas, & Hopko, 2009; Funderburk,
Pigeon, Shepardson, & Maisto, 2019) which led this intervention to consist of the five active
sessions from the BATD-R treatment manual according to instruction. Sessions took place
during 60-minute appointments once weekly for five weeks. This intervention took place at a
predominantly free primary care clinic in northern West Virginia where appointment length is
usually 60 minutes.
Patients with a provider appointment set between April 26, 2020 and July 24, 2020 were
screened for eligibility by the provider using the electronic medical record. Eligibility criteria for
patient participation was a diagnosis of major depressive disorder or elevated depressive
symptomology as evidenced by answering yes to either question on the PHQ-2. Exclusion
criteria included participation in any other psychosocial treatment. Each patient who agreed to
take part in the project was asked to sign an informed consent document.
During the first treatment session, each patient completed a Patient Health Questionnaire-9
(PHQ-9) and Behavioral Activation for Depression Scale (BADS) questionnaire. Throughout
treatment, patients completed Daily Monitoring Forms (DMF), the Life Areas, Values, and
Activities Form (LVAF), the Activity Selection and Ranking Form (ASRF), and Contract Forms
(CF). The DMF is a table that allows the patient to track their daily activities (see Appendix B).
The LVAF is a form the patient can use to identify their values in certain life areas and specific
activities that support these values (see Appendix C). The ASRF is a form the patient uses to
choose activities that support their values and then ranks these activities by difficulty (See
Appendix D). The CF is a form that patients use to encourage involvement from family and
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friends in their treatment (Appendix E). Each session in the revised manual was accompanied by
a completion checklist for the provider.
Each session in the revised manual was accompanied by a completion checklist for the
provider.
•

Session one included a discussion of depression, introduction to treatment rationale and
the daily monitoring form, and important points about the structure of treatment.

•

Session two included reviewing and troubleshooting the DMF, reviewing the treatment
rationale, and completing the LVAF.

•

Session three included reviewing DMFs, reviewing the LVAF, and completing the
ASRF.

•

Session four included reviewing DMFs and starting daily monitoring with planning
activities.

•

Session five included reviewing DMFs with activity planning, completing the CFs, and
completing a DMF for the week with activity planning.

•

Subsequent sessions included the continuation of review and activity planning.
Data from the completed PHQ-9 and BADS questionnaires pre- and post-intervention

were kept in a data table using random patient identification numbers, accompanied by a separate
master list. (Refer to Appendix F for data table.) This data table and master list was kept in a
locked box with a key kept by the project leader. All other documents completed by the patient
were stored in their electronic medical record.
Participating patients were supposed to attend five 60-minute sessions over the course of
five weeks. All visits were conducted according to the BATD-R manual. The provider completed
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a checklist for each session to ensure adherence to treatment. It was intended for each patient to
complete a post-treatment PHQ-9 and BADS during the last treatment session. Patients who
failed to attend at least three out of five treatment sessions were considered lost to follow-up.
Feasibility Analysis
The goal of this pilot study was to implement a behavioral activation intervention in the
primary care setting to improve the management of depression. It was implemented in a
community funded clinic that services low income, uninsured and underinsured patients. This
clinic is housed in the center of an urban area where most community resources reside for the
impoverished population. These resources include multiple food pantries and soup kitchens, a
drop-in center, homeless shelter, and department of human resources. The clinic itself serves as a
meeting place for a large portion of this population since most of the homeless population can be
found in this area. A significant number of patients who attend this clinic pass through multiple
times a day. While the location of this clinic is ideal for its population, most specialty clinics can
only be accessed using automotive transportation. Patients at this clinic rarely have funds for bus
rides, car services, or personal vehicles. Most patients will usually request continued treatment at
the primary care clinic.
In order to provide comprehensive behavioral activation treatment, one provider spent
about 60 minutes per session for a varying number of sessions with five patients. The provider
saw patients during usual clinic visits and evaluated PHQ-9 scores during the patient assessment
so provider salary was by the clinic as an organizational contribution. The budget for
administrative costs totaled approximately $3,000.
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Educational materials were available for the provider. The provider had a copy of the
BATD-R treatment manual. Session checklists from the treatment manual were used for each
individual patient. The scripts for depression discussion and treatment rationale from the first
session of the treatment manual were printed for each patient to use for discussion. Allowing for
error in printing, the budget for educational materials totaled approximately $45 from the project
leader’s personal funds.
Project supplies consisted of necessary materials for project intervention. These supplies
included two copies of the PHQ-9 and BADS, one daily monitoring form, one Life Areas,
Values, and Activities form, one Activity Selection and Ranking form, and two contract forms
per patient. These documents were kept in individually labeled file folders and all were kept in a
locked box. Pens were available for use by participating patients. Estimations take into account
printing errors. The budget for project supplies totaled approximately $75 from the project
leader’s personal funds.
The budget for this project totaled approximately $3,120. A majority of this budget was
collected from an organizational contribution and the rest from the project leader’s personal
funds. This includes monetary provisions for administrative costs, educational materials, and
project supplies. Implementation and organizational costs to the clinic were minimal since the
project leader is employed by the clinic and the intervention will be reimbursable as a normal
clinic visit. Contributions from the clinic were reflected as a portion of the current salary of the
provider already in place for provision of care. Return on investment was minimal for the clinic
due to the number of uninsured patients, but some income was generated by billing these visits
for Medicaid patient participants. However, insurance status was not considered when recruiting
participants for this project.

22

There were a few identifiable potential barriers to this project. The first potential barrier
was the need for increased appointments with the patient. The author considered that increasing
the number of follow-up appointments might put undue pressure on patients in this population
and lead to failed outcomes. This is similar to the barrier of patient compliance. As with most
populations, compliance with an aggressive treatment is likely to be low since it requires
increased patient effort and participation. The last barrier is patient literacy, including health
literacy. Patients in a low SES population tend to have low literacy levels, including health
literacy. This potentially impacted patient understanding of the disease process and treatment
rationale, and their ability to use written forms for monitoring. This last potential barrier was
addressed in the revised manual of BATD.
Evidence of Site Support
Support for this project was provided by the administration and clinical staff at the clinic
of interest. The clinic director gave written approval for the project to take place at the clinic.
Refer to Appendix G for evidence of site support.
Timeline
Planning for this project started in August of 2019. The study was enrolled in IRB and
approved in April of 2020. It was also enrolled in the Clinical Trials Center of Excellence and
the protocol was approved in July of 2020. Implementation began near the end of April 2020
during the COVID-19 pandemic and was completed near the end of July 2020. Due to issues
arising from the pandemic, enrollment in the project was extended by four weeks. The project
was concluded in August 2020. Refer to Appendix H for evidence of timeline.
Measurable Project Objectives
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The first aim of this project was to assess the feasibility of implementing this intervention
in this clinic population with a large percentage of patients struggling with mental illness, who
were potentially homeless, had a low income, and were either uninsured or underinsured. There
were five feasibility measures as denoted by Bowen et al. (2009) that were used as measurable
objectives for this aim: acceptability, demand, implementation, practicality, and limited-efficacy
testing. Acceptability is the extent to which an intervention is judged as suitable to the patient
and was measured by the intent to continue use of the intervention (Bowen et al., 2009). Demand
is the extent to which an intervention is likely to be used and was measured by the expressed
interest in the intervention and its actual use (Bowen et al., 2009). Implementation is the extent
to which an intervention is successfully delivered to patients and was measured by the success or
failure of its execution (Bowen et al., 2009). Practicality is the extent to which an intervention
can be carried out using the existing resources and was measured by the ability of the
participants to complete intervention activities (Bowen et al., 2009). Limited-efficacy testing is
whether or not the intervention can be successful in the intended population and was measured
by the presence of the intended effects on key variables (Bowen et al., 2009). Data gathered
from implementation of the intervention and patient participation was used to assess these
objectives.
The second aim of this project was to decrease overall PHQ-9 scores and increase overall
BADS scores using a psychosocial intervention. There were two measurable objectives for this
aim: patients with depression will show a decrease in overall PHQ-9 scores post-intervention,
and patients with depression will show an increase in BADS scores post-intervention. Data for
these objectives were measured using self-report information from the PHQ-9 questionnaire and
BADS questionnaire. Overall PHQ-9 scores and BADS scores were assessed before intervention
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for all patients, and after intervention for some patients. A paired t-test was used to determine if
there was a statistical difference between the pre- and post-data.
The third aim of this project was to increase medication treatment adherence in
conjunction with a psychosocial intervention. There was one measurable objective for this aim:
patients with depression will show an increase in medication treatment adherence postintervention. Data for this objective was supposed to be measured using self-report information
and pill counts during the first follow-up visit.
Data Analysis
Once post-treatment questionnaires were completed, data analysis began. Overall PHQ-9
and BADS scores were calculated for pre- and post-intervention data. Paired t-tests were used to
determine differences between them. Adherence to treatment by provider was measured using
checklists from each session to determine percentage of completion.
Results
Participation Summary
Patients were eligible for participation if they had a diagnosis of major depressive disorder
or elevated depressive symptomology as evidenced by answering yes to either question on the
PHQ-2. Exclusion criteria included participation in any other psychosocial treatment and
individuals less than 18 years of age. Five eligible patients agreed to participate in the study. Ten
eligible patients declined to participate in the study. All other patients with a diagnosis of MDD
or depressive symptomology were being seen by a counselor for other psychosocial treatment,
making them ineligible for BATD-R.
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Treatment Summary
Patient Number x

Pt. 1

Pt. 2

Pt. 3

Pt. 4

Sn. 1

X

X

X

X

Sn. 2

X

Sn. 3

X

Sn. 4

X

Sn. 5

X

Number of Sessions

X

Four patients were enrolled in the project study, and one patient made a verbal
commitment with a scheduled appointment to start the study. The first patient completed five
sessions of BATD-R and elected to continue with several sessions. The second patient completed
one session of BATD-R and then declined further participation. This patient has not been seen in
the clinic since the first session of BATD-R and no reason was given for discontinuing treatment.
The third patient completed two sessions of BATD-R, but the next session was cancelled by the
clinic due to COVID. The subsequent follow-up appointment was cancelled by the patient. Upon
resumption of treatment, this patient elected to postpone further follow-up due to a recent death
in the family. The fourth patient completed one session of BATD-R, but the next session was
cancelled by the clinic due to COVID. The patient then missed the next clinic appointment and
was unable to be reached by phone later in the week after rescheduling. This patient has not been
seen in the clinic since missing the follow-up appointment. The fifth patient did not attend the
first session of BATD-R and has not been seen in the clinic since agreeing to participate in the
study.
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Demographic Data Summary
Demographic data was obtained for three of the five participants. The second patient did
not provide demographic data and the fifth patient was not seen for the initial visit when
demographic data collection takes place. Demographic data included age, gender, ethnicity, level
of education, employment, housing, tobacco use, drug use, and alcohol use. Patients ranged in
age from 27 to 61 years old. Two patients were female, two patients are male. Three patients
considered themselves white. Level of education ranged from ninth grade to some college. Two
patients were unemployed, one patient was employed. Three patients lived with another person.
Two patients rented their residence and one patient owned their residence. Two patients lived in
a house and one patient lived in an apartment. Two patients smoked cigarettes and one patient
did not use tobacco. Two patients used illicit drugs and one patient did not. Two patients did not
use alcohol and one patient did use alcohol.
Evaluation Results
Aim 1 – The first aim of this project was to assess the feasibility of implementing this
intervention using five measurable objectives: acceptability, demand, implementation,
practicality, and limited-efficacy testing. Acceptability is the extent to which an intervention is
judged as suitable and was measured by the intent of participants to continue use of the
intervention. Only one participating patient attended the five required sessions of BATD-R,
while one patient completed two sessions, two patients completed one session, and one patient
completed zero sessions. The patient who completed five sessions elected to continue with
several sessions of BATD-R after the first five sessions. No other participants elected to continue
treatment. This means that 20% of the participants intended to continue use of the intervention.
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Demand is the extent to which an intervention is likely to be used, and was measured by
the expressed interest in the intervention and its actual use. Fifteen patients were eligible for the
project intervention, but only five elected to participate. Of those five patients, four attended at
least one session. This indicates that 33% of eligible patients expressed interest in the
intervention, and 80% of those who expressed interest completed at least one session. However,
only one patient completed all treatment sessions out of the five patients who expressed interest.
This means that only 20% of the patients who expressed interest completed the intervention.
Implementation is the extent to which an intervention is successfully delivered to patients
and is measured by the success or failure of its execution. Session checklists provided in the
BATD-R manual were kept for each patient during sessions. Each checklist showed that all
elements of each session were completed with the patient. This indicates that 100% of the
required components for treatment were delivered to patients during treatment sessions.
Practicality is the extent to which an intervention can be carried out using the existing
resources and is measured by the ability of the participants to complete intervention activities.
Participants were expected to complete one Daily Monitoring Form every day, one Life Areas,
Values, and Activities Form, one Activity Selection and Ranking Form, and at least one Contract
Form. Patients were provided with one copy of each form, and expected to secure their own
further copies of daily monitoring forms. Revised versions of the DMF for low literacy
participants were offered to each patient, but all patients declined. Out of the four patients who
attended the first session, three were capable of completing the DMF. This indicates that 75% of
participating patients could use the DMF. One patient had difficulty with the DMF because she
was illiterate. This indicates that 25% of participating patients could not use the DMF. Out of the
two patients who attended the second session, one had no difficulty using the LAVF while the
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second exhibited some confusion at using the form. This indicates that 50% of the participating
patients could use the LAVF form while 50% could not use the form. Of the one patient who
completed the other three sessions, there was no difficulty in using the ASRF or the CFs. This
indicates that 100% of the participating patients could use the ASRF and the CFs.
Limited-efficacy testing refers to whether or not the intervention can be successful in the
intended population and is measured by the presence of the intended effects on key variables.
Results for the effects of the intervention on key variables is limited due to high attrition rates
and missing data. From the complete pre- and post-data of one patient who completed the
intervention, there was a decrease in the PHQ-9 score and increase in the BADS score. From the
partial pre- and post-data of one patient who completed two sessions of the intervention, there
was an increase in the PHQ-9 score. There were no comparable data sets for the remaining three
participants. This indicates that the intervention had the intended effect on key variables in 25%
of the participating patients who completed at least one session.
Aim 2 – The second aim of this project was to decrease depression scores and increase daily
functioning scores as measured by the PHQ-9 and BADS questionnaires. Due to attrition, only
one patient completed pre- and post-data for both PHQ-9 and BADS questionnaires, while one
patient completed pre- and post-data for the PHQ-9 questionnaire. The average pre-intervention
PHQ-9 score for all participating patients was 15.25, while the average pre-intervention BADS
score for the same patients was 19. The average post-intervention PHQ-9 score for two of the
four participating patients was 12. Missing data did not allow for an average of the postintervention BADS score of participating patients. In the patient that completed the intervention,
the pre-intervention PHQ-9 score was 19 and the post-intervention score was 9. In this same
patient, the pre-intervention BADS score was 17 and the post-intervention score was 35. In the
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patient that completed two sessions of the intervention, the pre-intervention PHQ-9 score was 14
and the post-intervention score was 15. A paired t-test was used to compare pre- and postintervention scores for two participating patients on the PHQ-9. There was no significant
difference between the pre- and post-intervention PHQ-9 scores with p = 0.563. However, PHQ9 and BADS scores showed clinically significant improvements in depressive symptoms and
daily functioning in the patient who completed the intervention. The PHQ-9 scores showed no
clinically significant differences in the patient who completed two sessions of the intervention.
Aim 3 – The third aim of this project was to increase medication treatment adherence in
conjunction with a psychosocial intervention. This data was unable to be collected and the
provider was unable to determine if there was a statistical difference between the pre- and postdata.
Discussion and Recommendations
The theoretical framework for this project was based on The Theory of Symptom
Management. This theory provides a framework for exploring the relationship between
interventions and outcomes, as outlined by the structure of the association between symptom
experience, symptom management strategies, and symptom status outcomes (Smith & Liehr,
2008). According to The Theory of Symptom Management, patients experience distressing
symptoms and seek symptom management strategies that are followed by an evaluation of
symptom status outcomes where the symptom should be less frequent, intense, or distressing
(Smith & Liehr, 2008). The development, implementation, and evaluation of interventions is
supported by this framework due to its association between the concepts of symptoms, as
interventions are intended to improve symptoms. It is an especially apt framework for this
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project as it focuses on the evaluation of symptom outcomes after implementing an intervention
for symptom relief.
The feasibility evaluation of this project showed mixed results. Data suggests that the
intervention was not acceptable to the patient population, nor in high demand. Only a small
number of eligible patients were interested in the intervention, and an even smaller amount
actually participated in the sessions. Of those interested, only one patient completed the
intervention. While data for implementation suggests the intervention can be successfully
delivered, practicality seemed to be an issue. Completing the included intervention activity forms
was essential to success of the treatment and patients seemed to struggle with understanding the
required forms. Limited efficacy data also suggested that this intervention may not produce the
expected improvement in symptoms of depression or daily functioning in this population.
Producing adequate data for analysis of significance was difficult due to patient attrition.
Available data suggested there was no statistically significant difference in depressive symptoms
or daily functioning between pre- and post-intervention. Yet data did indicate a potential clinical
significance. The patient who completed two sessions of the intervention did not show a
clinically significant difference in depressive symptoms; however, data from the patient that
completed the intervention in its entirety suggested a clinically significant improvement in
depressive symptoms and daily functioning after the intervention.
While there were some promising findings, it is recommended that this project be phased
out and terminated at this facility. The feasibility of this project in a population of low income,
uninsured and underinsured patients is questionable. Patient interest in this behavioral treatment
was limited and data showed no statistically significant improvement in depression or
functioning. Also, this project did not produce enough data to determine clinical significance.
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Patient interest in mental health treatment may have been eclipsed by the COVID-19 pandemic
at this time. It could also account for the attrition rate of participating patients. When speaking of
attrition, it is important to note that patients with mental illness are more likely to miss follow-up
appointments, and those that miss follow-up appointments have a greater chance of losing
contact with the clinic (DeFife, Conklin, Smith, & Poole, 2010; Killaspy, Banerjee, King, &
Lloyd, 2000). These factors may have had an impact on the implementation of this project. It
may be possible to implement this project in a behavioral health center or integrated care center,
or a different primary care clinic with a population of patients that are more likely to attend
frequent clinic visits. Patients attending a behavioral health center may be more likely to
continue follow-up while patients at an integrated care center would receive comprehensive care
that may encourage continued clinic contact. Research literature shows that behavioral activation
is an effective treatment for depression but this project demonstrates that it may not be
appropriate in a low-income primary care clinic, especially during the COVID-19 pandemic.
The implementation of this project has positively impacted the care I provide for patients
with mental illness. The research undertaken during the planning phase of this project has
allowed me to more thoroughly understand the assessment and diagnosis of depression. It has
also allowed me greater knowledge of the available treatments for depression and their relative
effectiveness. The therapeutic relationships I built during the implementation phase of this
project has led me to greater empathy and compassion for patients with mental illness. Greater
understanding of the patients’ experience has improved my communication and allowed for
enhanced patient motivation. While analyzing feasibility and outcomes of this project during the
resolution phase I was able to better understand what patients desire from their treatment plan
and the capabilities of this population to engage in their treatment. The outcomes of this project
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suggest that patients in this population desire more of a therapeutic approach and are not highly
engaged in treatment activities. This realization led me to increase my use of motivational
interviewing techniques leading patients to higher levels of engagement and change. These
modifications in my practice are directly related to the knowledge I gained from this project.
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DNP Essentials
This project meets the first essential of “scientific underpinnings for practice” by using
nursing theory to evaluate practice approaches in a novel environment. Using the Theory of
Symptom Management, this psychosocial intervention was further developed and its
effectiveness validated in the primary care setting.
This project meets the second essential of “organizational and systems leadership for
quality improvement and systems thinking” by developing and evaluating care for certain
vulnerable populations. This psychosocial intervention has been revised for patients with mental
illness who belong to a low socioeconomic status or lack adequate healthcare coverage.
This project meets the third essential of “clinical scholarship and analytical methods for
evidence-based practice” by critically appraising existing literature and using synthesized
information to design and implement methodologies that promote effective patient care. The
literature review of this psychosocial intervention preceded the revision of intervention
guidelines which were implemented to promote patient wellness.
This project meets the fourth essential of “information systems/technology and patient care
technology for the improvement and transformation of health care” by demonstrating the ability
to develop and execute an evaluation plan using data extraction from practice information
systems. Completed health questionnaires used to evaluate the effect of this intervention became
part of the patient’s medical chart, and data from these documents were used to evaluate
intervention efficacy.
This project meets the fifth essential of “health care policy for advocacy in health care” by
developing and implementing institutional health care policy. This psychosocial intervention has
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the potential to become part of treatment guidelines for this population and become institutional
policy at primary health care clinics. The findings from this project can help to improve the
implementation of this intervention.
This project meets the sixth essential of “interprofessional collaboration for improving
patient and population health outcomes” by using effective communication and collaboration in
the development and implementation of practice guidelines. The project leader improved the use
communication skills to educate clinic providers and clinic staff on the use of this intervention
and encouraged collaborative teamwork to make it successful.
This project meets the seventh essential of “clinical prevention and population health for
improving the nation’s health” by including education as part of the intervention to promote
healthy behaviors that have an effect on population health. Using a psychosocial intervention,
this project promoted healthy behaviors in depressed patients that have an effect on this
particular population.
This project meets the eighth essential of “advanced nursing practice” by demonstrating
advanced levels of clinical judgment, systems thinking, and accountability in designing,
delivering, and evaluating evidence-based care to improve patient outcomes by designing,
implementing, and evaluating a psychosocial intervention in primary care. The project leader
revised the design, implemented, and evaluated an evidence-based psychosocial intervention that
can improve patient outcomes.
Nurses are known to value the holistic well-being of their patients. They establish
therapeutic relationships that promote a mutual trust and respect between patient and nurse. This
relationship often allows the patient to become an equal partner in their care and encourages
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participation in treatment. This is a unique attribute of the advanced practice nurse. The
intervention utilized in this study was a direct reflection of that partnership between provider and
patient and appropriate for use by advanced practice nurses.
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Appendix A
Author/Da
te

Purpose/Varia
bles

Design/Meth
od

Sample/Setti
ng

Data Analysis

Findings

Cuijpers, P.,
van Straten,
A., &
Warmerdam,
L. (2007).

To examine the
effects of activity
scheduling on
depression, the
relative effects of
activity scheduling
compared to other
treatments, and the
long-term effects.

Meta-analysis.
Comprehensive
literature search
(1966-2005)
through PubMed,
PsycINFO, Embase,
and Cochrane
Central Register of
Controlled Trials.
Collected primary
studies from 22
meta-analysis of
psychological
treatment of
depression.
Examined abstracts
of 777 studies and
selected ones
which focused on
activity scheduling.
Included studies in
which effects of
activity scheduling
on adults with a
depressive disorder
or an elevated level
of symptomology
were compared to
a control condition
or another
psychological or
pharmacological
treatment in a
randomized control
trial. No language
restrictions.
Considered
intervention
activity scheduling
when registration
of pleasant
activities and the
increase of positive
interactions
between a person
and his/her
environment were
the core elements
of the treatment.
Methodological
quality of the
studies was
assessed using 4
criteria by Higgins
& Green (2005).
Calculated effect
sizes using only
instruments from
studies that
explicitly measure

16 studies with a
total of 780
subjects met
inclusion criteria
and were
included.

Mean effect size
between activity
scheduling and
control condition
indicating a large
effect favoring
activity scheduling.

Authors
found clear
indications
that activity
scheduling is
effective in
the
treatment of
depression in
adults. The
overall effect
size of 0.87 is
large and
comparable
to effect sizes
found for
other
psychological
treatments
and
treatments
with
antidepressa
nts. Several
studies
compared AS
to CT and
indicated that
AS and CT are
equally
effective
including at
follow-up
periods up to
6 months.

The pooled effect
size between activity
scheduling and other
psychological
treatments was 0.13
indicating a small
effect favoring
activity scheduling
without significant
difference.
The pooled effect
size between activity
scheduling and
cognitive therapy
was 0.02 indicating a
small effect favoring
activity scheduling.
The pooled effect
size between activity
scheduling and
CT+AS was -0.01
indicating a small
effect favoring
CT+AS.
The pooled effect
size between CT and
a combination of
CT+AS was -0.16
indicating a small
effect favoring
CT+AS.
The effect size
between activity
scheduling and
antidepressant
medication was 0.26
indicating a small
effect in favor of
activity scheduling.
The effects of activity
scheduling compared
to a control condition
at follow-up ranged
from 0.88 at two
months to 0.54 at six
months indicating a
large and moderate

Apprais
al
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depression. To
calculate pooled
mean effect sizes,
the computer
program
Comprehensive
Meta-analysis was
developed.
Cochran’s
heterogeneity
statistic.

Dimidjian, S.,
Hollon, S.D.,
Dobson, K.S.,
Schmaling,
K.B.,
Kohlenberg,
R.J., Addis,
M.E., Gallop,
R.,
McGlinchey,
J.B., Markley,
D.K., Gollan,
J.K., Atkins,
D.C., Dunner,
D.L., &
Jacobson, N.S.
(2006).

To test the relative
efficacy of BA in
acute treatment of
major depression by
comparing it both
with CT alone and
with ADM in the
context of a placebocontrolled trial; to
test whether either
psychosocial
treatment was a
viable alternative to
ADM in the
treatment of
moderate to severe
depression.
Treatments included

Randomized
control trial.
Eligible participants
were randomly
assigned to a
treatment using a
computergenerated
randomization list
consisting of BA,
CT, ADM, or PLA.
Depression severity
was used as
stratification
variable during
randomization.
Scores on
pretreatment HRSD

effect respectively
suggesting some
support for the
effectiveness of
activity scheduling in
the long-term.
The pooled effect
size was 0.18
indicating a small but
nonsignificant
improvement from
post-test to followup. The change
between post-test
and 4-6 months
follow-up resulted in
a pooled effect size
of 0.03 indicating a
small effect. The
change from posttest to 7-12 months
follow-up was 0.53,
indicating a
moderate effect.

Participants
consisted of 241
individuals
between ages of
18 and 60 years
who met criteria
for major
depression
according to the
DSM-IV and
scored 20 or
higher on BDI-II
and 14 of greater
on the 17-item
Hamilton Rating
Scale for
Depression.
Recruitment

Effects of activity
scheduling at followup could be
compared to the
effects of CT at 1-2
months with a
pooled effect size of
0.02. Effects of
activity scheduling at
follow-up compared
to CT at follow-up at
4-6 months had a
pooled effect size of 0.13 indicating
nonsignificant
differences between
CT and activity
scheduling at followup. CT vs. activity
scheduling at one
year follow-up d =
0.30.
In high-severity
subgroup, significant
overall improvement
by time for all groups
on the BDI and on
evaluator rated
HRSD, p < 0.0001.
Participants in BA
improved
significantly more per
treatment than in CT
on both BDI
(p=0.029), and the
HRSD (p=0.038).
Participants in ADM
improved
significantly more per
treatment than in CT

Results of this
study indicate
that BA is
comparable
in efficacy to
ADM and
more
efficacious
than CT
among more
severely
depressed
patients.
Results also
provide
further
confirmation
of
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BA, CT,
antidepressant
medication (ADM) or
pill placebo (PLA).
Measures included
diagnosis,
depression severity,
adherence and
competence,
response and
remission.

were used to form
two groups of high
or low severity.
Participants were
assigned to
therapists within
modality based on
therapist
availability. BA
condition received
max of 24, 50-min
sessions over 16
weeks, generally
held twice weekly
for first 8 weeks
and once weekly
for second 8
weeks. CT
condition followed
the same protocol
regarding
frequency,
schedule, and
allotment of
treatment sessions
as the BA
condition. Both
ADM and PLA
conditions were
administered in a
triple-blind manner
during first 8 weeks
then the blind was
broken and PLA
participants were
offered their choice
of treatment at
study expense.
ADM was
administered in a
single-blind
manner for the
final 8 weeks.
Participants were
seen weekly for the
first 4 weeks and
biweekly thereafter
through week 16
(although PLA were
terminated at week
8). First
pharmacotherapy
session was 30-45
min and
subsequent
sessions lasted up
to 30 minutes.
Diagnosis was
measured using a
standardized
clinical interview,
depression severity
was measured
using a modified
17-item version of
the HRSD and the

occurred
between 1998
and 2001 from
media
advertisements,
referral from
local agencies,
and word of
mouth or
referral.
Participants were
excluded if they
had a dx of
psychosis or
bipolar dx,
organic brain
syndrome,
mental
retardation,
substantial and
imminent suicide
risk, current or
primary diagnosis
of alcohol or durg
abuse panic
disorder,
obsessivecompulsive
disorder,
psychogenic pain
disorder,
anorexia, or
bulimia, presence
of antisocial,
borderline, or
schizotypal
personality
disorder, or
nonresponse to
adequate trial of
CT or paroxetine
within the
previous year.

on both BDI
(p=0.007) and HRSD
(p-0.022). No sig diff
in the rate of
improvements
between BA and
ADM on BDI or HRSD
(p=0.80, p=0.96).
Using the BDI and
HRSD, ADM and BA
lie within the margin
of noninferiority,
with a probability
larger than 99.1%.
In low-severity
subgroup, there was
significant overall
improvement by time
for all groups on the
BDI (p<0.0001) and
the HRSD (p<0.0001).
No evidence of
differential
improvement over
time by treatment on
BDI or HRSD.
Among more
severely depressed
patients, overall
combined rates of
response and
remission based on
the BDI were 48% in
CT, 76% in BA, and
49% in ADM. On the
basis of HRSD overall
rates were 56% in CT,
60% in BA, and 40%
in ADM. Significantly
greater percentage of
BA participants met
BDI response criteria
compared with
receiving CT
(p=0.048). Rates of
remission highseverity subgroup
based on BDI were
40% in CT, 52% in BA,
and 42% in ADM. On
basis of HRSD, overall
rates of remission
were 36% in CT, 56%
in BA, and 23% in
ADM. No significant
differences between
treatments on BDI.
Results indicated
significant
differences between
treatments on the
HRSD (p=0.012) with
a significantly greater
percentage of BA
participants reaching

importance
of initial
severity in
analysis of
treatment
outcome
because
differential
treatment
effects were
observed
only among
those
patients who
were more
severely
depressed.
For more
severely
depressed
patients BA
and ADM
were
comparable
on self-report
and clinical
ratings and
BA brought a
significantly
greater
percentage of
participants
to remission
and retained
a great
percentage of
participants
in in
treatment.
Results
underscore
the value of
sustained use
of simple
behavioral
strategies,
such as goal
setting, selfmonitoring,
activityscheduling,
problemsolving, and
graded task
assignment in
the
treatment of
depression.
BA did
particularly
well in this
study. It was
at least as
efficacious as
ADM, even
among more
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Dobson, K.S.,
Hollon, S.D.,
Dimidjian, S.,
Schmaling,
K.B.,
Kohlenberg,
R.J., Gallop,
R.J., Rizvi, S.L.,
Gollan, J.K.,
Dunner, D.L.,
& Jacobson,
N.S. (2008).

To determine
enduring effects of
prior exposure to BA,
prior exposure to CT,
and continued
treatment with ADM
in the context of a
placebo-controlled
trial. To determine
whether effects of
prior psychosocial
treatments extended
beyond the
prevention of
relapse to the
prevention of
recurrence during a
2nd year follow-up
after acute

BDI-II. HRSD was
administered at
pre-, mid-, and
post-treatment and
as required. HRSD
was administered
at each session
during the first 8
weeks for ADM and
PLA participants.
BDI-II was
administered at
pre-, mid-, and
post-treatment and
as required.
Treatment
adherence was
measured using a
version of the
Collaborative Study
Psychotherapy
Rating Scale
modified to
accommodate
inclusion of BA, and
Cognitive Therapy
Scale for
competence of CT
delivery. Response
is significant
symptomatic
improvement and
remission is
improvement to
the point of being
asymptomatic
within normal
range. On HRSD
and BDI, response
was defined as at
least 50% reduction
from baseline and
remission was
defined as scores
less than or equal
to 7 on HRSD and
10 on the BDI.
Participants were
recruited from the
original Dimidjian
(2006) study and
consisted of 106
patients who had
been assigned to
active treatment
but no longer met
the diagnostic
criteria for MDD at
the end of the
acute phase of
treatment. Data
were available to
estimate risk to the
point of relapse or
recurrence for 92
of the 106 patients

Participants were
followed to the
point of relapse
or recurrence for
up to 2 years
following
response to
acute treatment.
1st year
compared prior
CT, BA, and ADM.
Participants who
had received
ADM were
randomized by
previous
assignment and
continued active
medication or

remission as
compared with ADM.
Among less severely
depressed, overall
rates of response
based on BDI were
65% in CT, 50% in BA,
and 56% in ADM. On
basis of HRSD overall
response rates were
60% in CT, 39% in BA,
and 47% in ADM. No
significant
differences between
treatments on BDI.
Rates of remission
based on BDI were
55% in CT, 44% in BA,
and 42% in ADM. On
basis of HRSD overall
rates of remission
were 50% in CT, 39%
in BA, and 33% in
ADM. No significant
difference between
treatments on BDI or
HRSD.

severely
depressed
participants,
and retained
a greater
proportion of
patients long
enough for
them to
benefit from
treatment.
BA was also
more
efficacious
than CT
among more
severely
depressed
participants.
Interest in BA
was based in
part on the
notion that it
would be a
more
exportable
treatment
that is easier
to implement
and train
than CT or
other more
complex
interventions.

Relapse: Especially
likely to occur at the
start of the 1st followup year, especially
for medication
responders
withdrawn onto
placebo (cPLA). Rates
of relapse during 1st
follow-up year were
39% for prior CT, 50%
for prior BA, 53% for
cADM, and 59% for
cPLA. Active
treatments were
superior to
withdrawal onto
placebo (p = 0.04).
Separately prior CT

Overall
pattern of
results
observed
indicates that
prior
treatment
with either
CT or BA has
an enduring
effect that is
at least as
efficacious as
continuing
patients on
medication
and that held
for the
prevention of
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treatment. Outcome
measures included
relapse and
recurrence. Relapse
is defined as the
return of the treated
episode of
depression, and in
this study as either
HRSD scores of 14 or
greater or PSRs of 5
or greater for 2
successive weeks
during the 1st year of
follow-up.
Recurrence is
defined as the onset
of a new episode of
depression, and in
this study as either
HRSD scores of 14 or
greater or PSRs of 5
or greater for 2
successive weeks
during the 2nd year of
follow-up.

who entered
follow-up period.

withdrawn onto
PLA at the
beginning of the
1st year follow-up
according to
predetermined 2week taper
schedule.
Patients in cADM
and cPLA
continued to see
pharmacotherapi
sts biweekly for
the first 2 months
and monthly
thereafter the
rest of the 1st
year follow-up.
At the end of the
1st year,
pharmacotherapi
sts discontinued
cADM patients’
medication using
the same taper
as used for cPLA
participants.
Patients in both
cADM and cPLA
were seen
biweekly during
the taper period
and then
assessed during
the 2nd follow-up
year. Participants
completed
assessment
instruments
biweekly for the
first 2 months of
the 1st year
follow-u phase,
at months 3, 6,
and 12, 13, 14,
18, and 24. Ad
hoc assessments
were conducted
whenever a new
episode of
depression was
suspected, on the
basis of elevated
HRSD scores, or
patient or
pharmacotherapi
st report.

was significantly
superior to cPLA (p =
0.02) and prior BA
demonstrated a
nonsignificant trend
(p = 0.09), but cADM
was not significantly
different from cPLA
(p = 0.33). Prior
exposure to CT
reduced risk for
relapse by 64%
relative to
medication
withdrawal. cADM
reduced risk for
relapse by about
33%. Prior exposure
to BA was associated
with a reduction in
risk for relapse by
51%, and is
comparable to the
effect typically
observed for
continuation of
medication.
Recurrence: Patients
in cADM were
withdrawn from
medication at the
beginning of 2nd year
follow-up. Rates of
recurrence during 2nd
follow-up year were
24% for prior CT, 26%
for prior BA, and 52%
for prior cADM.
Effect of prior CT and
BA showed a
nonsignificant trend
compared to the
effect of prior cADM
(p = 0.06). Prior
exposure to either CT
or BA reduced the
risk of recurrence by
about 63% relative to
medication
withdrawal. The
overall effect for
treatment was
significant (p = 0.04)
with both prior CT
and BA being
superior to
continuation of
medication followed
by medication
withdrawal. Prior CT
was significantly
superior to cADM (p
= 0.02) whereas prior
BA exhibited a
nonsignificant trend
in the same direction

relapse and
possibly
recurrence.
Evidence for
enduring
effect was
clearer for
prior CT than
BA but
differences
between two
psychosocial
interventions
never
approached
statistical
significance
and were
relatively
small in
magnitude.
The
indication
that BA may
also have an
enduring
effect
comparable
to CT, but not
for patients
successfully
treated with
medication, is
particularly
noteworthy.
Because
behavioral
ideas are
used
repeatedly
during acute
treatment,
they are
highly salient
and thus
recall is
increased at
times of
potential
relapse. BA is
implemented
in a manner
that is
intended to
both teach
coping skills
and reduce
further risk.
Although
antidepressa
nt
medications
generally are
safe and
efficacious,
there is little
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(p = 0.08). Prior
exposure to BA was
associated with a
reduction in risk of
47% relative to cADM
and prior CT was
associated with a
reduction in risk of
58%. CT and BA were
directly compared
with maximal power
provided by full 2year comparison and
did not significantly
differ (p = 0.57). CT
was associated with a
reduction in risk of
27% relative to prior
BA. Over one third of
patients initially
assigned to BA/CT
showed sustained
outcomes across the
course of acute
treatment and the 1st
follow-up year,
compared to less
than a quarter of the
patients initially
assigned to
pharmacotherapy.
Comparisons
revealed that only
prior CT had a
greater sustained
response than both
cADM. Across the 2nd
follow-up year, rats
of sustained recovery
were 35% for prior
CT and 28% for prior
BA. This indicates
that brief treatment
with either CT or BA
is as efficacious over
the long run as
keeping people on
ADM.

Ekers, D.,
Richards, D., &
Gilbody, S.
(2007).

To compare
behavioural
interventions for
depression to other
psychological
approaches and
controls.

Meta-analysis.
Database search
from inception to
January 2006
(including Medline,
EMBASE, PsycINFO,
Cochrane Library
DARE, CINAHL,
AMED, and British

20 studies, 1109
subjects
BT vs waiting
list/control/place
bo: 12 studies,
459 participants
from adult
community

BT vs. Waiting
list/placebo/control:
Large effect with a
pooled SMD
demonstrating highly
significant difference
in symptom level
scores favoring BT (p
< 0.001). Average

evidence that
they alter the
course of the
disorder.
Because
depression is
often chronic
or recurrent,
any
treatment
with an
enduring
effect is
particularly
worthwhile.
Even though
little
evidence was
found of a
preventive
effect for the
continuation
of
medication, it
was striking
how rapidly
even
recovered
patients
experienced
a recurrence
when
medication
was
withdrawn.
Overall,
current
results
suggest that
BA may have
an enduring
effect similar
to that
produced by
CT. Prior CT
was superior
to medication
withdrawal,
and prior BA
did almost as
well (at a
nonsignifican
t level). Each
was at least
as effective
as continued
medication.
Data showed
clear
evidence that
BT is an
effective
treatment for
depression
and provides
superior
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Nursing Index)
incorporating
randomized
controlled trial
filters. Additional
studies found using
reference lists. All
available RCT in
any language were
included,
participants aged >
or = 16 years,
treated in
community or
inpatient settings
with primary dx of
depression.
Excluded studies
including patients
with psychosis or
bipolar, substance
misuse, cognitive
impairment.
Interventions
included BT (based
upon rescheduling
of activities to
reintroduce
positive
reinforcement and
reduce avoidance),
treatment as
usual/control
(range of standard
treatments such as
waiting list, usual
GP treatment, inert
control conditions),
CBT/CT (directly
identified,
questioned, and
modified cognitive
responses to
situations and their
emotional
consequences),
brief
psychotherapy
(developing insight
and subsequent
character
development
through
interpersonal
relationships),
supportive
counseling (focus
upon therapist’s
use of core
relationship
conditions to
develop selfawareness by the
patient). Outcome
measures were
depression

sources. Control
interventions
were delayed
treatment,
treatment as
usual, relaxation.
Depression
severity was
assessed using
BDI, HAMD, or
both.
BT vs. CT/CBT: 12
studies with a
total of 476
patients from
adult community
sources.
Interventions
ranged from
supported
bibliotherapy,
brief therapy
with six 40-min
sessions to 24 50min sessions.
Depression
symptom level
was assessed
using either BDI
self-report or
HAMD assessor
rating scale.
BT vs.
psychotherapy: 3
studies with a
total of 166 adult
patients from
outpatient
community
sources, 2 using
older adults.
Psychodynamic
model from 1020 sessions.
Assessed
depression
symptom level
using BDI or BDI
& HAMD.
BT vs. supportive
therapy: 2
studies with 45
subjects
comprised of
university
students and
inpatients.
Interventions
ranged from six
20-min sessions
to eight 50-min
sessions.
Measured

dropout rate of
19.17% with no
differences between
intervention and
control (p = 0.86).
Greater rates of
recovery in BT (p =
0.03).
BT vs. CT/CBT:
Depression level post
treatment showed no
difference in effect
between BT and
CBT/CT was
identified with a
pooled SMD (p =
0.46). Depression
level at follow-up
showed no difference
in effect with a
pooled SMD (p =
0.28). No difference
in rates of dropout (p
= 0.67). Pooled
recovery rate of 55%
with no difference
between treatment
approaches (p =
0.72).
BT vs. psychotherapy:
Depression symptom
post-treatment
showed a positive
effect of BT with a
large pooled SMD (p
= 0.01). Depression
symptom level at
follow-up showed a
positive effect of BT
with a medium SMD
(p = 0.02). Average
dropout rate of
14.45% but no
difference between
studies observed (p =
0.11). Greater rates
of recovery were
observed in BT
compared to
psychotherapy (p =
0.01).
BT vs. supportive
therapy: Depression
symptom level at
post-treatment
showed a positive
effect of BT against
supportive therapy
with large SMD (p =
0.02).

outcomes to
control,
supportive
counseling,
and brief
psychotherap
y. BT and CBT
provided
equivalent
results with
no
statistically
significant
differences in
posttreatment
and follow-up
symptom
levels,
recovery
rates, or drop
outs. In
addition to
similar levels
of mean
symptom
improvement
, we observed
no difference
in recovery or
dropout,
indicating
that BT is as
effective and
acceptable as
CBT/CT. Such
findings
partially
endorse the
BT parsimony
hypothesis
advanced by
Jacobson and
colleagues.
BT may lend
itself to
shorter
training of
less-qualified
individuals
thus assisting
the current
scarcity of
therapist
availability
and
overwhelmin
g demand.
We found no
direct
evidence in
this review to
support such
an
assumption,
but when we

50

Funderburk,
J.S., Pigeon,
W.R.,
Shepardson,
R.L., & Maisto,
S.A. (2019).

To address the need
for brief depression
treatments in
primary care.
Intervention variable
was brief behavioral
activation
intervention,
measured variables
were patient
engagement,
satisfaction,
acceptability,
treatment response,
and fidelity.

symptom-level selfrated (BDI) or
clinician rated
(HAMD), and
recovery and
dropout rates were
entered as
dichotomous data.
Quality
assessment, data
extraction and
synthesis (data
from each trial at
post-treatment and
follow-up of 6
months or nearest
available data
synthesized using
Cochrane
collaboration
RevMan program),
data pooling,
exploration of
heterogeneity.

depression
symptom levels
by self-report BDI
and HAMD.

Pre-test/post-test
design without
randomization or
control. Open trial.
Eligible patients
completed a
baseline
assessment and
follow-up
assessment at 12
weeks. Participants
received two
appointments of
BA-PC with two
boosters spaced 23 weeks apart.
Content was
modified from the
original 10appointment brief
BA treatment
manual for
depression.
Booster appts did
not introduce new
content, but
reviewed material
from previous
appts, problem
solved barriers, and
set new goals.

Participants were
recruited from
two VHA primary
care clinics.
Patients who
screened positive
on PHQ-2 in the
previous month
were identified
by EMR and
contacted via
mail and
telephone. These
patients were
eligible if they
met criteria
including:
depressive
symptoms of at
least moderate
severity termed
PHQ-9 > or = 10,
no current mania
or psychosis, no
current dx of
bipolar, no
psychotherapy
for depressive
symptoms within
the past month,
no
antidepressants
or on stable dose
> 3 months, no
engagement in

Patient engagement:
Completed activity
logs for 2, 3, & 4
were 36%, 1%, and
32% resp. Patients
tried to enact 1 of
the goals set at prev
appt based on
discuss with mean
rating of 3.41, 3.01,
and 3.80.
Patient
satisfaction/acceptab
ility: mean CSQ rating
was 26.7 out of 35
indicating high level
of overall satisfaction
with number &
duration of appts,
and in-person
format. Seven
patients cited ease of
access as main
reason for
satisfaction.
Reported high
likelihood of cont to
engage in activities
after study to
improve mood.
Treatment response:
within subjects t-test
revealed significant
reduction in
depressive symptoms

examined the
impact on
level of
training of
those who
had delivered
BT in metaregression,
we did not
find that
superior
outcomes
were
associated
with ‘higher’
level
qualifications.
In summary,
BT for
depression is
an effective
intervention
that has
equal, if not
better,
outcomes
than
alternative
and currently
recommende
d therapies.
Results of this
study support
feasibility,
acceptability,
and utility of
BA-PC.
Patients
reported high
levels of
satisfaction
with
intervention
overall, and
with specific
BA-PC
characteristic
s such as
length,
duration, and
format.
Patients
endorsed
high
likelihood of
continued
engagement,
indicating
high levels of
acceptance.
Patients
perceived
improvement
in depressive
symptoms,
corroborated
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psychotherapy or
stable
psychotherapy
for anxiety or
SUD > 3 months,
no current
inpatient
hospitalization.
Total of 222
veterans
screened, 87
eligible to
participate, 36
agreed to
participation, 32
fully eligible to
continue, 22
completed entire
study. No
significant
differences in
age, race,
baseline level of
depressive
symptoms.

p = 0.001. No
statistically sig
difference in report
of morbid/suicidal
ideation, 6/11
reported no thoughts
of suicide in the past
2 weeks or thoughts
less often.
Fidelity: Appt 1 & 2 =
all core content
delivered to 95% of
pts. 26/32
participants
completed appts 1 &
2, and a majority of
patients (n=20) also
completed two
boosters. Average 12
days between appts,
appts 1&2 lasted
average of 34- and
29-minutes resp.
Booster appts lasted
28 minutes on
average.

by decreased
PHQ-9 scores,
and patients
across all
levels of
depressive
severity saw
improvement
s. BA-PC may
not
completely
resolve
depressive
symptoms
and a
majority of
patients did
not report a
clinically
significant
decrease in
symptoms,
68%
treatment
response
rates suggest
a majority of
patients in
the study
reported
symptom
reduction
such that 9pts
demonstrate
d clinically
significant
improvement
and 6 pts
reported an
improvement
consistent
with a
treatment
response.
This study
showed that
a brief
behavioral
activation
intervention
was wellreceived by
pts in primary
care and that
it could be
delivered
with high
fidelity, and
suggested
that BA-PC
may result in
an
improvement
in depressive
symptoms.
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Gawrysiak,
M., Nicholas,
C., Hopko,
D.R. (2009).

To use an RCT to
assess the efficacy of
single-session
individualized BA
intervention based
on the more
comprehensive BATD
protocol.

RCT. Preliminary
power analysis
conducted.
Potential
participants were
recruited through
an online study
description and
websites
highlighting
counseling services
for students in
need. Participants
completed a BDI
and demographic
questionnaire for
eligibility.
Participants 18
years and older
who scored 14 or
higher on the BDI
and were not
presently
undergoing
pharmacological or
psychological
treatment for
depression were
included, excluded
if involved with
psychotherapy
within the last 2
years, active
suicidal intent,
current psychosis,
or bipolar disorder.
Treatment protocol
represented major
modification of
original BATD
intervention in that
it was reduced to a
one-session
treatment which
resulted in five
fewer weeks of
activity scheduling
making it a
nonprogressive
approach to
activating, in which
a greater number
of behaviors were
targeted for
activation
immediately, and
omission of
behavioral
contracting
strategies to
decrease rewards
for depressive
behaviors. 90-min
individual
intervention
session by 1 of 2

Introductory
psychology
students
recruited from a
public
Southeastern
university who
received credit
for participation.
All but 2 eligible
students agreed
to participate in
the study, and all
who participated
completed the
study. 30
students overall,
BATD treatment
n=14 and no
treatment n=16.
Recruitment
processes
involving selfreferral and
highlighting
aspirations for
depression
treatment as a
desired
participant
attribute

Adherence to
treatment was
measured with the
weekly behavioral
checkout that was
returned to clinician
at post-treatment. All
outcome variables
were examined with
a 2x2 repeated
measures analysis of
variance. Clinical
significance of prepost differences was
assessed using
Cohen’s d statistic
where effect sizes of
0.2, 0.5, and 0.8 are
considered small,
medium, and large.
Significant Group x
Time interactions
were evident on both
the BDI (p < 0.01) and
EROS (p < 0.001).
Large effect sizes on
both the BDI (1.61)
and EROS (1.14)
revealed clinically
significant
improvements. BAI
scores did not yield a
significant Group x
Time interaction (p =
0.25, d = 0.36). A
trend toward
increased social
support in BATD
group relative to
control condition at
post treatment (p =
0.08) that was
characterized by a
moderate effect size
(d = 0.70). Reliable
change indices (RCI)
calculated for each
measure indicated
that on the BDI 93%
of individuals in the
BATD group
significantly
improved, compared
with only 31% in the
control group. On the
EROS, 64% of
individuals in the
BATD group
improved, where 0%
of participants in the
control group
demonstrated
clinically significant
change. MSPSS data
revealed that 29% of
individuals in the

There was
strong
support for
the efficacy
of 2 weeks of
BA in
attenuating
symptoms of
depression
and
increasing
responsecontingent
positive
reinforcemen
t. There was
also
encouraging,
but not
statistically
significant,
evidence that
BATD might
show some
utility in
creating a
stronger and
more
rewarding
social support
system.
Change-score
data
supported a
strong
relationship
between
decreased
depression
and increased
RCPR, and
the good
compliance
rate in this
study
increases
confidence
that
improvement
was
associated
with BA and
increased
environment
al reward. An
important
consideration
of current
findings is
that pre-post
treatment
changes
resulted from
a single 90minute
session of
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male doctoral
students in clinical
psych. Eligible
students were
contacted by
telephone and
asked to
participate. Within
3 days of
completing the
online depression
measure,
participants were
randomly assigned
to either the BATD
treatment or notreatment control
group. Each
participant then
had their initial
session in which
they were exposed
to either 90 min of
BATD or a general
discussion about
research
requirements and
their participation
in the study.
Follow-up sessions
were scheduled 2
weeks later, during
which time
outcome measures
were administered,
behavioral
checkout form
returned, and
participants
debriefed.
Measures included
BDI (assesses the
severity of
depression
symptoms), EROS
(assesses
environmental
reward and RCPR,
or response
contingent positive
reinforcement with
higher scores
suggesting
increased
environmental
reward), BAI
(measures
cognitive and
somatic symptoms
of anxiety), and
MSPSS (assesses
the adequacy of
social support from
family and
significant others

BATD group
improved
significantly
compared with only
6% in the control
group. RCI analyses
of the BAI yielded
comparable findings
across groups with
36% of individuals in
the BATD group and
31% of participants in
the control group
demonstrated
clinically significant
change. Calculated
pre-post treatment
change scores to
determine the
degree to which
efforts to structure
guided activities and
engender
environmental
reward were
effective e in
reducing depressive
affect. Although
causality cannot be
inferred, changescore data indicate
strong relationships,
whereby the
magnitude of
increased
environmental
reward was strongly
correlated with
decreased
depression (p < 0.01)
and anxiety (p <
0.05), as well as
increased social
support (p < 0.01)

BATD.
Although
follow-up
data were
not obtained,
results
suggest that
brief BA may
effectively
minimize
depressive
symptoms in
the short
term. In
summary, the
single-session
BATD
intervention
resulted in
significant
reductions in
depressive
symptoms
and increased
environment
al reward.
These
findings
suggest that
abbreviated
treatments
may have
some utility
toward
effectively
and
efficiently
reducing
depressive
symptoms in
moderately
depressed
university
students.
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Luoto, K.E.,
Lindholm,
L.H.,
Paavonen, V.,
Koivukangas,
A., Lassila, A.,
Leinonen, E.,
& Kampman,
O. (2018).

To explore the
benefits of BA in a
heterogeneous
group of depressed
patients in a
naturalistic setting
and to compare BA
with treatment as
usual in terms of
functional recovery,
service use, dropout,
and mortality.

where higher
scores suggest
decreased social
support).
BCT (observational
intervention study)
used to assess the
impact of clinical
intervention in
routine settings, in
contrast to RCT
which usually
assess the specific
intervention in
ideal settings. To
study the impact of
the selected
intervention in real
life setting of
psychiatric
secondary services.
Comparisons were
made with a
control group
representing as
similar patient
population as
possible treated
with TAU methods
in the same area.
Consecutive
patients who were
referred to adult
psych services
because of
depressive
symptoms, anxiety,
selfdestructiveness,
insomnia, or
substance related
problems were
screened using the
BDI. Those with BDI
score equal to or
greater than 17 at
the screening were
included in the
intervention group
(n = 242). The
control group (n =
205) was recruited
from a hospital
district database of
psychiatric
outpatient clinics
not participating in
the ODS study from
October 2009December 2012
and from the same
psychiatric hospital
ward before the
start of the ODS.
Patients with a new
referral to adult

Recruited from
five psychiatric
outpatient clinics
and one
psychiatric
hospital ward
(Finland) during
October 20092013.

Improvement of
depressive symptoms
in intervention
patients was
analyzed using
MADRS scores. Mean
score for intervention
patients at baseline
was 23.2 pts, 13.1 at
6 months, 9.93 at 12
months, and 8.31 at
24 months. Change in
MADRS was
statistically
significant in every
follow-up period. At
12- and 24-months
follow-up the
estimated
improvement in GAF
score was
significantly better in
the intervention
group (p = 0.036). At
six months a similar
difference was not
found. Sensitivity
analysis was
performed by
excluding patients
with personality
disorder as
secondary clinical
diagnosis (n = 44).
Results were similar
with the total sample
analysis with GAF
estimates between
intervention and
control groups at 6
months (p = 0.057),
12 months (p =
0.006), and 24
months (p = 0.002).
There was no
between-group
differences in
number of outpatient
visits during any
follow-up period.
Need for
hospitalization was
measured in every
follow-up period and
number of
hospitalized patients
was similar in the
intervention and
control groups during
all periods. Among
patients who were
hospitalized at

Since only
patients with
psychotic or
organic
pathologies
were
excluded this
study was
heterogeneo
us with
various
comorbidities
and therefore
representativ
e of the usual
patient
population in
everyday
practice.
Depressive
symptoms
among the
intervention
group
patients
seemed to
alleviate
compared to
baseline
during the 2
years of
follow-up.
Results
suggest that
BA is a useful
tool although
strong
conclusions
can’t be
drawn about
the benefits
compared to
TAU.
Intervention
patients
showed a
greater
improvement
in functional
ability than
control.
Functional
recovery has
a
considerable
effect on
daily life and
is particularly
relevant from
patients’
point of view.
Intervention
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psych services
were selected in
chronological order
if their BDI score
was greater than or
equal to 17 at
admission and the
AUDIT score was
available. Control
group patients
were matched with
the intervention
group patients by
clustering
according to the
current psych
hospital contact
(inpatient/outpatie
nt), AUDIT score in
4 categories, and
BDI score in 2
categories.
Characteristics
were mainly similar
between the
groups, only the
baseline GAF score
(p = 0.035) and the
frequencies of
personality
disorders as a
secondary
psychiatric
diagnosis (p =
0.037) were
statistically
significant different
between the
groups. For the
intervention group,
baseline
assessment was
based on the Cube
Method (integrated
assessment
method for
comorbid
psychiatric and
substance use
disorders in clinical
settings) and used
to decide which
patients would be
additionally treated
with motivational
interviews.
Depressive
symptoms were
rated using the
MontgomeryAsberg Depression
Rating Scale
(MADRS) and level
of functioning was
assessed using the
Global Assessment

baseline, number of
patients hospitalized
during follow-up
periods was also
similar between
groups. There were
no between group
differences in the
number of patients
who dropped out in
any period (p = 0.79,
p = 0.86, p = 0.51,
respectively). There
were 4 deaths in the
intervention group
and 7 deaths in the
control group (p =
0.23).

did not
change the
need for
inpatient
treatment in
the
intervention
group.
Dropout rates
indicated that
adherence to
treatment
was similar in
both groups.
In this study,
mental health
workers with
various
backgrounds
received
short-term
training in BA
and delivered
the
intervention
successfully.
This indicates
that this
intervention
could
enhance the
treatment of
depression in
the existing
psychiatric
health care
system.
Depressive
symptoms
improved and
there was a
trend
towards
better
functional
recovery
among
patients
treated with
BA compared
to TAU.

56
of Functioning
scale (GAF). For
control group, all
data were collected
retrospectively
from hospital
district patient
registers. In
intervention group,
BA and
antidepressant
medication were
used for 239 of the
patients and
motivational
interviews were
used during the
first appointment
in patients having
alcohol use
problems (baseline
AUDIT greater than
or equal to 11).
Minimum duration
of BA was set at 4
appointments.
Median number of
sessions was 6.5.
Decision to start
medication was
based on clinical
evaluation at
baseline and 6
weeks by the
treating physician.
If baseline MADRS
score was 20 or
more, medication
was started and
the dose was
elevated if
necessary or
changed from SSRI
to SNRI as needed.
All patients in the
control group were
treated in public
psychiatric
secondary care in
the same
organization as the
intervention group
over the same time
period. Control
patients received
TAU according to
protocols of
respective
treatment unit and
followed-up
according to the
case notes at 6, 12,
and 24 months by
estimating GAF
scores and
obtaining
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Mazzucchelli,
T., Kane, R., &
Rees, C.
(2009).

To identify all
randomized
controlled studies of
BA, to determine the
effect of this
approach, and to
examine the
differential
effectiveness of
variants.
Interventions
included pleasant
activities, selfcontrol, contextual
behavioral
activation, and
BATD.

information about
possible alcohol
use. For both
groups, info about
frequency of visits,
number of hospital
days, and dropouts
were collected
from patient
registers at 6, 12,
and 24 months
follow-up.
Meta-analysis.
Searched PsycINFO
and MEDLINE
databases for
articles published
between January
1970 and
September 2008
that included the
terms activity
scheduling,
behavioral/behavio
ural activation,
pleasant events, or
pleasant activities.
Studies were
included if effects
of BA on typically
developing adults
with depressive
disorder or
elevated levels of
depressive
symptomology
were compared
with a control
condition or
another
psychological or
active
pharmacological
treatment in a RCT.

BA vs. Control
conditions – The
effect of BA against
control was large
with a pooled effect
size of 0.78
demonstrating a
highly significant
difference favoring
BA. BA vs. Other
conditions –
Negligible pooled
effect size of -0.01
between treatments
was nonsignificant.
Subgroup analyses
indicated that the
pleasant activities
variant of BA yielded
a small effect in favor
of CBT/CT, selfcontrol variant
yielded negligible
effect in favor of
CBT/CT, and
contextual variant
yielded small effect
in favor of BA. Effect
sizes of different
variants of BA were
not found to differ
significantly from
each other. Effects at
follow-up – BA vs.
control at 1-3 month
follow-up was large
with pooled effect of
0.78, demonstrating
highly significant
difference favoring
BA; at 7-12 month
follow-up effect was
small at 0.08 and
nonsignificant in
favor of BA. BA vs.
CBT/CT at 1-3, 4-6, 712, and 13-24
months effect size
was small and
nonsignificant with
an effect size ranging
from -0.10 in favor of
CBT/CT to 0.05 in
favor of BA. BA vs.

Results
indicate that
BA is
effective in
the
treatment of
depression.
Individuals
with elevated
scores on
self-report
depression
measures,
overall effect
size in favor
of BA over
control is
large and
comparable
with the
effect size
found by
previous
metaanalyses.
Patients
meeting
diagnostic
criteria for
MDD, overall
effect size
remained
large and
significant.
Comparisons
of BA with CT
of CBT
indicated that
these
treatments
were equally
effective.
There is
evidence that
BA has
equivalent
effects to
CBT/CT for up
to 24 months.
Although
more recent
variants of
BA, such as
contextual
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psychotherapy or
other treatments at
1-3 months showed
pooled effect size of
0.23 indicating a
small, nonsignificant
difference in favor of
BA; BA vs.
psychotherapy only
at 4-6 and 7-12
months effect sizes
were large but
nonsignificant in
favor of BA.

Richards, D.A.,
Ekers, D.,
McMillan, D.,
Taylor, R.S.,
Byford, S.,
Warren, F.C.,
Barrett, B.,
Farrand, P.A.,
Gilbody, S.,
Kuyken, W.,
O’Mahen, H.,
Watkins, E.R.,
Wright, K.A.,
Hollon, S.D.,
Reed, N.,
Rhodes, S.,
Fletcher, E., &
Finning, K.
(2016).

To establish clinical
efficacy and costeffectiveness of BA
compared with CBT
for adults with
depression.

Randomized,
controlled, openlabel, noninferiority trial.
Patients were
recruited using
patient records of
general practices
and psychological
therapy services for
patients with
depression,
identified by
depression codes.
Practices/services
contacted patients
to seek permission
for researcher
contact, research
team interviewed
those that
responded and
assessed for

Recruited from
primary care and
psychological
therapy services
in Devon,
Durham, and
Leeds. Eligible
participants were
adults 18 years
and older who
met diagnostic
criteria for MDD
according to
standard clinical
interview.
Exclusion criteria
were patients
receiving
psychological
therapy, alcohol
or drug
dependence,
acute suicidal or

Between Sept 26,
2012 and April 3,
2014 authors
recruited 440
participants,
randomizing 221
participants to the BA
group and 219 to the
CBT group.
Participants received
an average of 11.5 BA
sessions or 12.5 CBT
sessions. Found no
evidence of
inferiority between
mITT or PP
populations. Found
no evidence of a
significant betweengroup treatment
interaction across the
mITT or PP group
with primary

BA, showed
greater
effects than
earlier
variants, all
produced
effects of
similar
magnitude
and
differences
between
them were
not
significant.
Focused
evidence
review
indicated that
contextual BA
has the
strongest
evidence
base and
satisfies the
APA’s
Division 12
Task Force’s
probably
efficacious
designation
for the
treatment of
MDD, and
could be
argued that
the BA
approach in
general
satisfies the
wellestablished
designation.
BA for
depression is
not inferior
to CBT in
terms of
reduction of
depressive
symptoms
and is more
cost-effective
than is CBT.
Economic
analyses
were driven
by lower
costs of
MHWs who
delivered BA
compared
with more
experienced
psychological
therapists
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eligibility. Patients
were randomly
assigned to groups
using computergenerated
allocation, and
stratified by
severity according
to PHQ-9 scores,
antidepressant
use/nonuse, and
recruitment site. A
computer-based
system allocated
the first 20 patients
to each group on a
truly random basis,
in subsequent
participants
allocation was
minimized to
maximize the
likelihood of
balance in
stratification
variables across the
two groups.
Authors developed
clinical protocols in
line with published
treatment
protocols, advice
from international
collaborators, and
NICE
recommendations
for duration and
frequency of
BA/CBT. MHWs
and therapists
delivered a
maximum of 20
sessions over 16
weeks, with the
option of 4
additional booster
sessions if desired
by patients. All
core components
of BA & CBT were
delivered by week
8. Sessions were in
person, lasting 60
minutes. Specific
BA techniques
included
identification of
depressed
behaviors, analysis
of triggers and
consequences of
depressed
behaviors,
monitoring of
activities,
development of

attempted
suicide in the
past 2 months,
cognitively
impaired, or had
bipolar disorder
or psychosis.
Recruited from
patient records
of general
practices and
psychological
therapy services
for patients with
depression.

outcome at 12
months as stratified
by depression
severity,
antidepressant use,
and recruitment site.
Found that BA was
not different from
CBT in anxiety,
depression status,
depression-free days,
or anxiety diagnoses
for either the mITT or
PP populations at 12
months. Between
61% and 70% of mITT
and PP participants in
both groups met
criteria for recovery
from depression in
response to
treatment at 12
months with no
difference in the
proportions of
patients in each
group who recovered
or responded. Found
no evidence of a
difference between
the CBT and BA
groups over the
period of the trial as
indicated by a
nonsignificant time
by treatment effect
interaction for both
mITT and PP
populations. Found a
significant difference
in mean
interventions costs
between the two
groups in favor of BA
(p < 0.0001), but no
differences in
categories of cost or
in total cost. Mean
health state utility
scores according to
EuroQoL-5D-3L were
slightly higher in the
BA group than CBT
across the entire
follow-up period with
resultant QALY
(Quality Adjusted
Life-Years) also
higher for BA, but the
QALY difference was
not significant. Costs
were lower and QALY
outcomes better in
the BA group than in
the CBT group. BA
was significantly less

who routinely
deliver CBT.
Results
substantiate
the
hypothesis
that BA is as
effective as
CBT and its
simplicity
renders BA
suitable for
delivery for
junior MHWs
with no
professional
training in
psychological
therapies.
Findings
could have
substantial
implications
for scalability
of
psychological
treatment for
depression
internationall
y given the
greater
availability
and ease with
which a BA
workforce
could be
trained than
could a CBT
workforce.
Results of this
study
challenge the
dominance of
CBT. Findings
suggest that
health
services
globally could
reduce the
need for
costly
professional
training and
infrastructure
, reduce
waiting
times, and
increase
access to
psychological
therapies.
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alternative goaloriented behaviors,
scheduling of
activities, and
development of
alternative
behavioral
responses to
rumination. Followup assessments
were done at 6, 12,
and 18 months.
Quality and
adherence to
treatment was
assessed. Primary
outcome was selfreported
depression severity
using the PHQ-9 at
12 months.
Secondary
outcomes were
PHQ-9 scores at 6
and 18 months,
DSM-IV diagnostic
status, number of
depression free
days between
follow-ups
(structured clinical
interview) and
health-related
quality of life at 6,
12, and 18 months
(36-item Short
Form Survey).

costly than CBT, so
BA continues to have
a higher probability
of being costeffective than does
CBT at the NICE
threshold.
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Appendix F
PHQ9 Pre

BADS
Pre

PHQ-9
Post

BADS
Post

Change
in PHQ9

Change
in
BADS

1

19

17

9

35

-10

+18

2

12

21

N/A

N/A

N/A

N/A

3

14

14

15

N/A

+1

N/A

4

16

24

N/A

N/A

N/A

N/A

19

12

N/A

Patient

Average 15.25
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